Gene expression profile identifies distinct molecular subtypes and potential therapeutic genes in Merkel cell

Umair Ali Khan Saddozai1, Fengling Wang1, Yu Cheng2

  • 1Department of Preventive Medicine, Institute of Biomedical Informatics, Cell Signal Transduction Laboratory, Bioinformatics Center, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.

Translational Oncology
|August 11, 2020
PubMed

Insights

Merkel cell carcinoma (MCC) can be classified into two molecular subtypes. These subtypes, linked to different cellular pathways, suggest distinct therapeutic targets for this rare skin cancer.

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer.
  • MCC incidence is rising in the elderly and immunosuppressed.
  • Eighty percent of MCC cases are linked to Merkel cell polyomavirus (MCPyV).

Purpose of the Study:

  • To identify distinct molecular subtypes of MCC.
  • To explore potential subtype-specific therapeutic targets.
  • To advance understanding of MCC oncogenesis.

Main Methods:

  • Gene expression profiling was used to analyze MCC samples.
  • Statistical analysis identified two consistent molecular subtypes.
  • Pathway analysis was performed on differentially expressed genes.

Main Results:

  • Two distinct molecular subtypes of MCC were identified.
  • Subtype I MCCs involve spliceosome, DNA replication, and cellular pathways.
  • Subtype II MCCs are associated with TNF and MAPK signaling pathways.

Conclusions:

  • Molecular subtyping offers a promising approach for MCC prognosis.
  • Subtype-specific therapeutic targets include PTCH1, CDKN2A, AURKA for Subtype I, and MCL1, FGFR2 for Subtype II.
  • Findings advance understanding of MCC subtypes and inform targeted therapy development.